Antibody Discovery Services
MPSA-AB5000 is rapid, simple and highly sensitive by measuring binding via reporter cell line and can determine specificity and preclinical safety of biotherapeutics conveniently.
Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.
Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.
Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.